2
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Breast Neoplasms
96
Rectal Neoplasms
45
Colorectal Neoplasms
45
Carcinoma, Non-Small-Cell Lung
31
Esophageal Neoplasms
28
Esophageal Squamous Cell Carcinoma
24
Stomach Neoplasms
22
Lung Neoplasms
20
Pancreatic Neoplasms
19
Squamous Cell Carcinoma of Head and Neck
18
Colonic Neoplasms
18
Sarcoma
16
Neoplasms
16
Adenocarcinoma Of Esophagus
15
Ovarian Neoplasms
14
Neoplasm Metastasis
14
Head and Neck Neoplasms
14
Carcinoma, Hepatocellular
14
Prostatic Neoplasms
13
Urinary Bladder Neoplasms
12
Uterine Cervical Neoplasms
10
Inflammatory Breast Neoplasms
9
Fallopian Tube Neoplasms
9
Osteosarcoma
8
Central Nervous System Neoplasms
8
Carcinoma, Intraductal, Noninfiltrating
8
Kidney Neoplasms
7
Carcinoma, Ovarian Epithelial
7
Recurrence
6
Multiple Myeloma
6
Interventions
Nivolumab
20
Ipilimumab
10
Surveys and Questionnaires
7
Paclitaxel
7
linrodostat
6
Standard of Care
6
Sirolimus
5
Gemcitabine
5
Bevacizumab
5
temsirolimus
4
relatlimab
4
Pemetrexed
4
Interviews as Topic
4
Docetaxel
4
Carboplatin
4
ARRY-334543
4
Vorinostat
3
Erlotinib Hydrochloride
3
Dasatinib
3
Cetuximab
3
regorafenib
2
olaparib
2
apatinib
2
anlotinib
2
abemaciclib
2
Trastuzumab
2
Sunitinib
2
Sorafenib
2
Olanzapine
2
N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Advanced Cancer
×
Neoadjuvant Therapy
×
Clear all
NCT04257786
2020-02-06
ovarian cancer
Assiut University
Phase NA
Unknown
80 enrolled